Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Business Overview: BMS is a global pharmaceutical and healthcare company organized into four reportable segments: Pharmaceuticals, Oncology Therapeutics Network (OTN), Nutritionals, and Other Healthcare. The company focuses on the discovery, development, and sale of pharmaceuticals, infant formulas, and medical devices.
Significant Restatement: The filing includes a "2003 Restatement" correcting historical accounting policies and errors related to revenue recognition (consignment model for wholesaler sales), tax contingency reserves, and cash classification. All prior period data presented in this summary is on a restated basis.
Key Financial Metrics
| Metric (in millions) | 2003 | 2002 (Restated) | 2001 (Restated) |
|---|---|---|---|
| Net Sales | $20,894 | $18,106 | $18,044 |
| Earnings from Continuing Operations | $3,106 | $2,067 | $1,871 |
| Net Earnings | $3,106 | $2,137 | $4,662 |
| Diluted EPS (Continuing Ops) | $1.59 | $1.06 | $0.95 |
| Operating Cash Flow | $3,512 | $945 | $5,372 |
| Long-Term Debt | $8,522 | $6,261 | $6,237 |
| Cash & Cash Equivalents | $2,444 | $2,367 | $4,552 |
| Working Capital | $4,388 | $1,573 | N/A |
Margins: Net earnings margin for continuing operations was 14.9% in 2003, up from 11.4% in 2002. Gross margin was 63.7% in 2003.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15% to $20.9 billion, driven by a 9% volume increase, 2% net price increase, and 4% favorable foreign exchange impact. U.S. sales rose 14%, while international sales rose 18%.
- Earnings Surge: Earnings from continuing operations increased 50% to $3.1 billion. This was primarily due to higher sales and the absence of the $1.2 billion in litigation settlements, asset impairments, and in-process R&D write-offs recorded in 2002.
- Debt Increase: Long-term debt rose to $8.5 billion from $6.3 billion, primarily due to the issuance of $1.0 billion in fixed-rate notes and $1.2 billion in floating-rate convertible debentures in late 2003 to fund U.S. operations and repay short-term borrowings.
- Segment Performance:
- Pharmaceuticals: Sales grew 16% to $14.9 billion. Key drivers included PRAVACHOL (+25%) and PLAVIX* (+31%).
- OTN: Sales grew 18% to $2.2 billion.
- Nutritionals: Sales grew 11% to $2.0 billion.
- Other Healthcare: Sales grew 8% to $1.7 billion.
Guidance, Outlook, and Risks
2004 Outlook:
- Exclusivity Losses: Management estimates net sales reductions of $1.2 to $1.3 billion in 2004 due to loss of exclusivity for products including the metformin franchise (GLUCOPHAGE*), TAXOL (Europe), MONOPRIL, and PARAPLATIN.
- Offsetting Growth: Expected losses will be offset by growth in in-line products (PLAVIX*, AVAPRO*, SUSTIVA), recently launched products (ABILIFY*, REYATAZ), and the newly approved ERBITUX*.
- Margin Pressure: Product mix changes (loss of high-margin exclusivity products) are expected to pressure margins.
Key Risks and Contingencies:
- PLAVIX* Litigation: The patent for PLAVIX* (approx. $2.5 billion in 2003 sales) is subject to litigation. An adverse outcome could lead to generic competition as early as 2005, which would be material to results.
- Legal Proceedings: The company faces significant pending lawsuits regarding wholesaler inventory issues, pharmaceutical pricing, and product liability (SERZONE, PPA). Management believes the aggregate impact beyond current reserves could be material.
- Restatement Impact: The 2003 Restatement corrected errors in revenue recognition and tax accounting. While material weaknesses in internal controls were remediated in 2003, a "reportable condition" regarding income tax accounting remains and is expected to be remediated by the end of 2004.
Investor Verification Checklist
- Restatement Details: Verify the specific impact of the 2003 Restatement on prior period comparability, particularly regarding the consignment revenue model and tax reserves.
- PLAVIX* Patent Status: Monitor the status of the PLAVIX* patent litigation, as the outcome is critical to future revenue projections.
- Exclusivity Timeline: Confirm the timing of generic entry for key products (PARAPLATIN, GLUCOPHAGE*, TAXOL) to assess the accuracy of the $1.2–$1.3 billion sales reduction forecast for 2004.
- Legal Reserves: Review Note 22 for updates on the $250 million reserve established in Q4 2003 for wholesaler inventory and pricing issues, and assess the potential for additional charges.
- Debt Structure: Analyze the terms of the new $1.2 billion convertible debentures issued in 2003 and their impact on future dilution and interest expense.